Next Article in Journal
Educators’ Interprofessional Collaborative Relationships: Helping Pharmacy Students Learn to Work with Other Professions
Next Article in Special Issue
Restrictions to Pharmacy Ownership and Vertical Integration in Estonia—Perception of Different Stakeholders
Previous Article in Journal / Special Issue
General Practitioners and Chronic Non-Malignant Pain Management in Older Patients: A Qualitative Study
Article Menu

Export Article

Open AccessArticle
Pharmacy 2016, 4(2), 16;

Falsified Medicines—Bridging the Gap between Business and Public Health

Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Universiteitsweg 99, Utrecht 3584CG, The Netherlands
Author to whom correspondence should be addressed.
Academic Editor: Keith A. Wilson
Received: 30 October 2015 / Revised: 7 March 2016 / Accepted: 23 March 2016 / Published: 28 March 2016
(This article belongs to the Special Issue Social Pharmacy)
Full-Text   |   PDF [192 KB, uploaded 28 March 2016]


The pharmaceutical industry is one of the most regulated industries in the world. While legislation is necessary to protect patients, too much legislation is said to hamper innovation and increase medicine prices. Using qualitative methods such as interviews and document analysis, we investigated the role of private stakeholders in the EU policymakers’ decision to initiate legislation to combat falsified medicines in 2008. Our results show that the pharmaceutical industry, brand owners in particular, were strong proponents of legislation to combat falsified medicines. Their support was not fueled by fear that falsified medicines would harm patients or their own business, but rather because legislative action in this area would advance policies that benefit their businesses objectives. The brand owners framed the issue to policymakers as best to support their business objectives. In general, supply chain actors lobbied for stricter requirements in order to challenge competitors. In the end, the Falsified Medicines Directive may have suffered from company influence not by addressing the primary problem of falsified medicines, but rather by creating additional legislation that benefits the supply chain actors. View Full-Text
Keywords: falsified medicines directive; pharmaceutical policy; European commission; multiple streams framework falsified medicines directive; pharmaceutical policy; European commission; multiple streams framework
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Borup, R.; Traulsen, J. Falsified Medicines—Bridging the Gap between Business and Public Health. Pharmacy 2016, 4, 16.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmacy EISSN 2226-4787 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top